- Home
- ENGN vs RCEL Comparison
ENGN vs RCEL Comparison
Compare ENGN & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- RCEL
- Stock Information
- Founded
- ENGN 1999
- RCEL N/A
- Country
- ENGN Canada
- RCEL United States
- Employees
- ENGN N/A
- RCEL N/A
- Industry
- ENGN
- RCEL Medical/Dental Instruments
- Sector
- ENGN
- RCEL Health Care
- Exchange
- ENGN Nasdaq
- RCEL Nasdaq
- Market Cap
- ENGN 191.1M
- RCEL 136.7M
- IPO Year
- ENGN N/A
- RCEL N/A
- Fundamental
- Price
- ENGN $3.51
- RCEL $5.38
- Analyst Decision
- ENGN Buy
- RCEL Strong Buy
- Analyst Count
- ENGN 7
- RCEL 4
- Target Price
- ENGN $23.29
- RCEL $16.50
- AVG Volume (30 Days)
- ENGN 76.2K
- RCEL 296.2K
- Earning Date
- ENGN 09-09-2025
- RCEL 08-07-2025
- Dividend Yield
- ENGN N/A
- RCEL N/A
- EPS Growth
- ENGN N/A
- RCEL N/A
- EPS
- ENGN N/A
- RCEL N/A
- Revenue
- ENGN N/A
- RCEL $71,661,000.00
- Revenue This Year
- ENGN N/A
- RCEL $57.16
- Revenue Next Year
- ENGN N/A
- RCEL $36.69
- P/E Ratio
- ENGN N/A
- RCEL N/A
- Revenue Growth
- ENGN N/A
- RCEL 41.35
- 52 Week Low
- ENGN $2.65
- RCEL $4.71
- 52 Week High
- ENGN $11.00
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- ENGN 48.11
- RCEL 49.79
- Support Level
- ENGN $3.25
- RCEL $5.61
- Resistance Level
- ENGN $3.98
- RCEL $6.04
- Average True Range (ATR)
- ENGN 0.26
- RCEL 0.32
- MACD
- ENGN -0.00
- RCEL 0.14
- Stochastic Oscillator
- ENGN 54.37
- RCEL 74.44
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.